Pịa ebe a ma ọ bụrụ na nke a bụ ntọhapụ mgbasa ozi gị!

Ọhụrụ gbasara ọgwụ mgbochi ọrịa kansa na China mara ọkwa

Innovent Biologics, Inc. (Innovent), ụlọ ọrụ biopharmaceutical nke ụwa na-emepụta, na-emepụta ma na-ere ahịa ọgwụ dị elu maka ọgwụgwọ ọrịa cancer, metabolic, autoimmune na ọrịa ndị ọzọ bụ isi, na NeoCura Bio-Medical Technology Co., Ltd. NeoCura), onye ndu AI-enyere RNA precision medicine biotech ụlọ ọrụ kpebisiri ike iwulite usoro ọgwụ ọhụrụ RNA zuru ụwa ọnụ, taa na-ekwupụta ọnụ na ha abanyela na nkwekọrịta nkwekọrịta iji mee nyocha ụlọ ọgwụ na China na ngwakọta ọgwụgwọ nke sintilimab. sitere na Innovent na ọgwụ mgbochi neoantigen ahaziri iche NEO_PLIN2101 sitere na NeoCura.

Print Friendly, PDF & Email

Innovent ga-arụkọ ọrụ na NeoCura na China iji nyochaa nchekwa, pharmacokinetics, pharmacodynamics na mbido mbụ nke ọgwụgwọ ngwakọta na-eji sintilimab sitere na Innovent na NEO_PLIN2101 sitere na NeoCura na ndị ọrịa cancer, iji kwalite mmepe ụlọ ọgwụ nke ngwakọta immunotherapy maka ọtụtụ etuto siri ike wee kwado n'okpuru. ngwa nyocha Ọhụrụ Drug (IND) na National Medical Products Administration (NMPA) n'ọdịnihu dị nso.

Dr. Liu Yongjun, Onye isi oche Innovent, kwuru, sị: "Anyị nwere mmasị na pipeline R & D dị iche iche nke NeoCura na ndị otu nyocha mba ụwa, na anyị nwere obi ụtọ ịbanye na nkwekọrịta usoro a iji chọpụta uru ahụike nke sintilimab na ngwakọta na ọgwụ mgbochi neoantigen maka etuto siri ike. . Innovent nwere pipeline siri ike nwere ikike siri ike na ọgwụ mgbochi ọrịa na ihe gbasara ọrịa kansa. Ugbu a, anyị nwere ọgwụ ọhụrụ akwadoro ma malite na China ma ga-enwe ihe karịrị ọgwụ 10 ọhụrụ ka a ga-ewepụta n'ime afọ 2-3 na-esote. Usoro ikpo okwu anyị jikọtara ọnụ achịkọtala R&D siri ike, mmepe ụlọ ọgwụ na ikike ịzụ ahịa yana dịkwa mma maka ndị mmekọ n'ụlọ na mba ọzọ. Anyị na-atụkwa anya ịga n'ihu inyocha ohere ọhụrụ na ịgbasa ihe ngosi na ịkwalite nrụpụta ọgwụgwọ sintilimab yana mgbakwunye na usoro ọgwụgwọ ọhụrụ. Anyị na-atụ anya nkwado zuru oke na nke miri emi n'etiti akụkụ abụọ ahụ n'ọdịnihu. "

Dr. Wang Yi, onye guzobere NeoCura, kwuru, sị: “Ka ọ dị ugbu a, ọgwụ mgbochi neoantigen bụ usoro ọgwụgwọ na-apụta na-agbanwe agbanwe n'ụwa niile. NeoCura nọ na-elekwasị anya na R&D nke ọgwụ mgbochi tumor neoantigen kemgbe e guzobere ya, na-atụ anya imeri ihe ịma aka nke immunotherapy dị ugbu a na ọgwụgwọ etuto siri ike site na itinye teknụzụ ọhụrụ. Mmekọrịta ya na Innovent ga-arụ ọrụ synergistic nke ọgwụ mgbochi neoantigen ahaziri onwe ya na ọgwụ mgbochi monoclonal na ijikọ ọnụ na-enyocha mmetụta ụlọ ọgwụ nke ọgwụgwọ ngwakọta na ọgwụgwọ nke etuto siri ike, nke a na-atụ anya na ọ ga-eme ka ọnụọgụ nzaghachi ebumnobi nke ọrịa kansa immunotherapy wee weta ohere ọhụrụ. maka usoro ọgwụgwọ ọrịa cancer. "

Print Friendly, PDF & Email

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ bụ Linda Hohnholz.

Ahapụ a Comment